CBX2 and hepatocellular carcinoma: Consistently, our study provided evidence that knockdown of CBX2 could simultaneously alleviate two pro-cancer histone modification (H3K27me3 and H2AK119ub), and this therapeutic strategy may especially benefit HCC patients who bear an aberrant epigenetic landscape like subtype Group A patients.